

Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711.

AUTHOR(S)

Nyree Crawford, Manuela Salvucci, Christian T. Hellwig, Frank A. Lincoln, Ruth E. Mooney, Carla L O'Connor, Jochen HM Prehn, Daniel B Longley, Markus Rehm

CITATION

Crawford, Nyree; Salvucci, Manuela; Hellwig, Christian T.; Lincoln, Frank A.; Mooney, Ruth E.; O'Connor, Carla L; et al. (2018): Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711.. figshare. Journal contribution. <https://hdl.handle.net/10779/rcsi.10789853.v1>

HANDLE

[10779/rcsi.10789853.v1](https://hdl.handle.net/10779/rcsi.10789853.v1)

LICENCE


CC BY-NC-SA 4.0

This work is made available under the above open licence by RCSI and has been printed from <https://repository.rcsi.com>. For more information please contact repository@rcsi.com

URL

https://repository.rcsi.com/articles/Simulating_and_predicting_cellular_and_in_vivo_responses_of_colon_cancer_to_combined_treatment_with_chemotherapy_and_IAP_antagonist_Birinapant_TL32711_/10789853/1

Sup. Fig. 1



Supplemental Figure 1: Mathematical simulations of *in vitro* and *in vivo* apoptosis competency subsequent to MOMP. (A-D) The behaviour of ensembles of 1,000 cells per treatment condition was mathematically modelled for HCT116 cells *in vitro* (A) and *in vivo* (B) or LoVo cells *in vitro* (C) and *in vivo* (D). Cell ensembles were parameterised as described in the main manuscript. Each line represents the behaviour of one cell in the modelled ensemble. High amounts of substrate cleavage indicate that modelled cells are capable of executing apoptosis efficiently. Absent substrate cleavage or low amounts of substrate cleavage indicate failure to efficiently execute apoptosis. The simulation results indicate that post-MOMP heterogeneity is particularly prominent at *in vivo* conditions.